How many analysts have analysed Cellular Biomedicine (CBMG)?
The number of analysts covering Cellular Biomedicine (CBMG) is 1.
Cellular Biomedicine (CBMG) Forecast, Price Target & Analyst Ratings
NASDAQ:CBMG
Current stock price
19.75
0 (0%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Cellular Biomedicine (CBMG).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $19.75 to mean target of N/A, Based on 1 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
60.00%
CBMG was analyzed by 1 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about CBMG.
In the previous month the buy percentage consensus was at a similar level.
Only 1 analysts analyzed CBMG. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A